Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Sumeyra DERİN"'
Autor:
Nilay Sengul SAMANCİ, Emir CELİK, Ezgi DEGERLİ, Melih KASAP, Kerem ORUC, Sahin BEDİR, Sumeyra DERİN, Nihan SENTURK OZTAS, Burc Cagrı POYRAZ, Zeynep Hande TURNA, Fuat Hulusi DEMİRELLİ
Publikováno v:
Namık Kemal Tıp Dergisi, Vol 8, Iss 2, Pp 138-144 (2020)
Aim:Sleep disorders are one of the most common problems in patients with malignancy and they severely decrease the quality of life. We sought to investigate the frequency of sleep disturbances, its quantity, quality and possible correlation with rela
Externí odkaz:
https://doaj.org/article/4ab956db61934316b6cc2b3a7bf179c0
Publikováno v:
Medicine. 101(48)
Wernicke's encephalopathy, a disorder caused by thiamin deficiency, is characterized by a classical triad of encephalopathy, ataxia, and ophthalmoplegia. Although alcoholism is the most common predisposing factor, it can also be associated with nonal
Autor:
Fuat Demirelli, Nilay Sengul Samanci, Duygu Ilke Cikman, Nihan Şentürk Öztaş, Sahin Bedir, Emir Celik, Ezgi Degerli, Kerem Oruc, Nebi Serkan Demirci, Mehmet Karadag, Sumeyra Derin
Publikováno v:
Journal of Oncology Pharmacy Practice. 27:1665-1673
Introduction Erlotinib is an effective treatment option for EGFR-mutant non-small cell lung cancer. It is important to predict patients who will respond better to erlotinib. We designed this study to investigate the effect of renal insufficiency (RI)
Autor:
Emir Celik, Sahin Bedir, Nebi Serkan Demirci, Omer Bagcilar, Kerem Oruc, Ela Bicki, Burak Caglar Erol, Nilay Sengul Samanci, Ezgi Degerli, Sumeyra Derin, Fuat Demirelli
Publikováno v:
Melanoma Research. 30:477-483
This study aimed to assess whether dabrafenib/trametinib and vemurafenib/cobimetinib treatments are associated with a change in skeletal muscle area (SMA) and total fat-free mass (FFM) assessed by computed tomography (CT), and to compare the efficacy
Autor:
Gulin Alkan, Kerem Oruc, Sumeyra Derin, Nihan Şentürk Öztaş, Emir Celik, Fuat Demirelli, Nilay Sengul Samanci, Ezgi Degerli, Sahin Bedir, Nebi Serkan Demirci
Publikováno v:
Journal of Medical Virology
Undoubtedly, cancer patients have suffered the most from the COVID‐19 pandemic process. However, cancer is a heterogeneous disease, and each patient has responded differently to COVID‐19. We aimed to describe the clinical characteristics and outc
Autor:
Emir, Celik, Nilay Sengul, Samanci, Sumeyra, Derin, Sahin, Bedir, Ezgi, Degerli, Kerem, Oruc, Nihan Senturk, Oztas, Gulin, Alkan, Abdulhalim, Senyigit, Zeynep Hande, Turna
Publikováno v:
Northern clinics of Istanbul. 9(1)
Extrapulmonary neuroendocrine carcinoma (EP-NEC) is a rare tumor type, and a standard therapy for EP-NEC has not yet been established. The purpose of this research was to explore the overall survival (OS) and therapeutic effects of platinum-etoposide
Autor:
Melih Kasap, Sahin Bedir, Kerem Oruc, Fuat Hulusi Demirelli, Nilay Sengul Samanci, Emir Celik, Ezgi Degerli, Sumeyra Derin, Burç Çağrı Poyraz, Nihan Senturk, Zeynep Turna
Publikováno v:
Namık Kemal Tıp Dergisi.
Publikováno v:
Journal of B.U.ON. : official journal of the Balkan Union of Oncology. 24(5)
The purpose of this study was to determine the influence of the neutrophil-lymphocyte ratio (NLR) and the platelet-lymphocyte ratio (PLR) on antiEGFR and bevacizumab efficacy in metastatic colorectal cancer patients.All metastatic colorectal cancer p
Autor:
Ender, Dogan, Mahmut, Ucar, Teoman, Sakalar, Sumeyra, Derin, Oktay, Bozkurt, Mevlude, Inanc, Metin, Ozkan
Publikováno v:
Journal of B.U.ON. : official journal of the Balkan Union of Oncology. 23(4)
Non-small-cell lung cancer (NSCLC) constitutes 80-85% of all lung cancers. Patients with advanced-stage NSCLC may benefit from chemotherapy. Gemcitabine and cisplatin is a well-established therapy for this malignancy. Recently, biweekly administratio
Autor:
Mustafa Ozguroglu, Emir Celik, Fuat Demirelli, Nilay Sengul Samanci, Ezgi Degerli, Sahin Bedir, Sumeyra Derin, Kerem Oruc
Publikováno v:
Annals of Oncology. 30:xi19
Background Clinical trials have demonstrated the benefit of immune-checkpoint inhibitors (ICIs) for many cancer types. With the widespread use of ICIs, we are facing challenges in the management of immune-related adverse events(irAEs). It is extremel